PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc.

Company overview

• Nevada corporation developing cellular therapies for cancer using a proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box®.
• Current product candidate generation is called CypCaps™.
• The technology places encapsulated, genetically engineered human cells near tumors to convert a chemotherapy prodrug into its active form, aiming to enhance localized efficacy and limit systemic exposure.

Core technology and product candidate

• Cell-in-a-Box® produces pinhead-sized, porous cellulose capsules that contain genetically modified live cells. Capsules can be cryopreserved until use.
• Encapsulation protects cells from environmental stresses during manufacturing and delivery, supporting higher cell viability and continued production of activating enzymes.
• Capsules are primarily cellulose (cotton) and are described as bioinert, intended to reduce immune attack on the therapeutic cells.
• Development has focused on pancreatic tumors using cells engineered to express cytochrome P450 enzymes (for example, CYP2B1) to activate prodrugs near the tumor.
• The approach targets perivascular, localized chemotherapy and may support improved surgical resection outcomes for locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC).

Leading indication and regulatory trajectory

• Primary focus: LAPC, with the goal of enabling or improving surgical resection and patient outcomes through localized prodrug activation.
• An Investigational New Drug (IND) application was submitted to the FDA in 2020; the FDA placed the IND on clinical hold in October 2020 and requested additional nonclinical, CMC, biocompatibility and comparability data, plus detailed manufacturing and control information.
• A Scientific Committee was formed on November 17, 2023, to review development programs and potential new frameworks with SG Austria and its subsidiaries. Development spending has been curtailed pending the committee’s recommendations and regulatory clarity.
• Orphan Drug designation has been granted for the pancreatic cancer program in both the U.S. and the European Union.

Key regulatory and development activities

• Stability studies on the frozen (-80°C) clinical trial product candidate with timepoints up to 24 months.
• Completed FDA-requested studies including Master Cell Bank (MCB) stability, biocompatibility testing, and genetic sequence confirmation of the CYP2B1 gene insert.
• Ongoing evaluations of microcatheter and syringe compatibility, system and device testing, and shelf-life/lot-specific release testing.
• Data compilation and submissions to the FDA continue as the company addresses nonclinical and manufacturing questions; the FDA’s decision on resuming a new clinical protocol is pending.

Intellectual property and licensing

• The technology is licensed through arrangements with SG Austria Pte. Ltd. and related entities under Asset Purchase Agreements and amendments.
• The program depends on Cell-in-a-Box® technology, associated trademarks, and know-how concentrated in SG Austria.
• The company and SG Austria are evaluating the framework and scope of their ongoing relationship.

Manufacturing, supply chain and materials

• Austrianova Singapore Pte. Ltd. (Austrianova) is the sole source of the encapsulation process for the oncology program and is responsible for acquiring raw materials, including cellulose sulfate.
• Past and ongoing supply chain delays and possible liquidity constraints at Austrianova are identified as risks to supply integrity and continuity.
• Additional manufacturing activities have been performed to support regulatory readiness, including capsule-syringe compatibility testing, syringe break/glide force testing, and capsule exposure to contrast media.

Clinical and regulatory pathway outside the U.S.

• The company is considering foreign regulatory pathways, including EU and UK processes and the harmonization under the EU Clinical Trials Regulation and MHRA alignment with EU procedures.

Organizational and staffing context

• As of April 30, 2026, the company reported two full-time employees and several consultants (physicians, scientists, regulatory and clinical operations experts) supporting R&D and regulatory work.

Market, competition and positioning

• The company operates in a competitive pancreatic cancer treatment landscape that includes Abraxane/gemcitabine and FOLFIRINOX regimens and development programs from other biotech and pharmaceutical companies.
• The Cell-in-a-Box® platform is positioned to offer advantages in cell survivability, cryopreservation, targeted prodrug activation, and perivascular treatment strategies near tumors.

Notable cautions and state of the business

• The company is development-stage with limited near-term commercialization until regulatory clearance and demonstration of safety and efficacy.
• Development spending has been reduced while the Scientific Committee reviews program priorities and relationship terms with SG Austria.
• Manufacturing success, regulatory approvals, and the ability to raise capital are key uncertainties for the path forward.

Contact and corporate information

• Headquarters: Las Vegas, Nevada
• Website: www.pharmacyte.com